Figure 3.

Rates of AEs of special interest with baricitinib in RCTs, a PMS study in Japan and in the general RA population [76,117,118,119,120]. ^a Herpes zoster incidence is higher in Asia compared to North America and Europe [121]. AEs, adverse events; BARI, baricitinib; excl., excluding; IR, incidence rate; MACE, major adverse cardiovascular events; NMSC, non-melanoma skin cancer; PMS, post-marketing surveillance; PY, patient-years; RA, rheumatoid arthritis; RCT, randomised controlled trial; VTE, venous thromboembolism; YFU, years follow-up.